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ABSTRACT
Background: The efﬁcacy of sequential adjuvant trastuzumab (aTZ) after
chemotherapy in women with early-stage human epidermal growth
factor-2 (HER2/neu)-positive breast cancer reported by the updated Her-
ceptin Adjuvant (HERA) trial appears less favorable than originally
reported. Based on these updated results, we estimated the cost-utility
(CU) of sequential aTZ relative to chemotherapy alone in terms of incre-
mental cost per quality-adjusted life-year (QALY) gained.
Methods: A Markov model estimated incremental costs and outcomes of
12 months of aTZ after adjuvant chemotherapy in women with HER2/
neu-positive breast cancer over a 25-year horizon. The model incorporated
four broad health states (disease-free, local recurrence [LCR], distant
recurrence [DCR], death), stratiﬁed with or without symptomatic car-
diotoxicity. Baseline event rates and 3-year relative risk (RR = 0.75) were
derived from the HERA trial. As the duration of the beneﬁt remains
uncertain, the analysis considered 5-year and 3-year duration of beneﬁt in
two scenarios. Costs and utility weights were from the literature. The
analysis took a direct payer perspective, with costs reported in 2007
Canadian dollars. Costs and QALYs were discounted by 3% annually.
Results: The mean CU of sequential aTZ at a 25-year horizon was
$72,292 per QALY gained in the 5-year scenario and $127,862 per QALY
gained in the 3-year scenario. Results were particularly sensitive to the
magnitude and duration of carryover beneﬁt.
Conclusions: The CU of sequential aTZ is primarily dependent on the
magnitude and duration of beneﬁt. Further clinical research is required to
establish the optimum sequence and duration of aTZ therapy and clarify
the magnitude and duration of treatment beneﬁt.
Keywords: breast cancer, cost-utility, net-beneﬁts, relative risk,
trastuzumab.
Introduction
Human epidermal growth factor-2 (HER2/neu) protein overex-
pression and gene ampliﬁcation is observed in 20% to 25% of
women with breast cancer and is generally associated with a
more aggressive disease biology and a poorer prognosis relative
to cases without HER2/neu overexpression [1–3]. Trastuzumab
(Herceptin®) is a recombinant humanized monoclonal antibody
targeting HER2/neu receptors and has been shown to improve
median progression-free and overall survival when added to che-
motherapy for HER2/neu-positive breast cancer in the metastatic
setting [4–7].
Initial results from clinical trials of adjuvant trastuzumab,
used concurrently or sequentially to adjuvant chemotherapy,
reported an approximately 50% relative improvement in disease-
free survival and 30% relative improvement in overall survival
with trastuzumab for early-stage HER2/neu-positive breast
cancer [8–11]. On the basis of these extraordinary results, tras-
tuzumab was approved as adjuvant therapy for early-stage
HER2/neu-positive breast cancer, despite the relatively short
median follow-up reported in the trials, and the observed cardiac
toxicities and considerable incremental costs associated with its
use [12–15].
Although both the sequential and concurrent approaches are
accepted as providing signiﬁcant clinical beneﬁt, the sequential
approach appeared to offer equivalent efﬁcacy with a lower risk
of cardiotoxicity. Updated results from the HERA trial with an
additional year of follow-up, however, suggest that the relative
beneﬁt of sequential adjuvant trastuzumab may be less favorable
than originally reported [8,16]. Based on these updated results,
we undertook an economic evaluation to estimate the cost-utility
(CU) of sequential adjuvant trastuzumab after chemotherapy for
early-stage HER2/neu-positive breast cancer compared to che-
motherapy alone in terms of incremental cost per quality-
adjusted life-year (QALY) gained in a Canadian setting.
Methods
Economic Model
An economic model was developed in Excel (Microsoft Corpo-
ration, Redmond, WA) to estimate the long-term costs and out-
comes of 12 months of adjuvant trastuzumab after adjuvant
chemotherapy for HER2/neu-positive breast cancer, compared to
observation alone in a hypothetical cohort of 1000 women based
on HERA trial participants. A 25-year analysis horizon was used
to reﬂect the average life expectancy in this cohort. The model
took a Markov approch by deﬁning a ﬁxed number of possible
health states and modeling the probability of transitioning from
one health state to another during a speciﬁed time period, or
cycle. The costs and health consequences of being in each health
state were then aggregated over a deﬁned number of cycles, or
time horizon [17]. Costs and QALYs were both discounted by
3% annually. All assumptions used in the model are outlined in
Table 1.
The analysis used the net beneﬁt approach to calculate the
expected CU and the associated 95% conﬁdence interval (CI).
The net beneﬁt framework calculates the hypothetical net mon-
etary beneﬁt (NMB) of a new program or technology by weight-
ing incremental health outcomes (DE) by threshold willingness-
to-pay (l) for a unit of health outcome (e.g., per QALY) and
subtracting the incremental cost (DC) [18]:
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NMB E C= −Δ Δλ
If, for a particular willingness-to-pay (l), NMB is greater than
zero, monetized “value” is greater than cost, and the program or
technology can be considered cost-effective. By setting NMB to
zero, the net beneﬁt framework can be reformulated as the con-
ventional CU statistic:
NMB E C= ⋅ − =Δ Δλ 0
Δ ΔE C⋅ =λ
λ = Δ
Δ
C
E
Unlike the conventional incremental cost-effectiveness ratio, the
net beneﬁt approach facilitates the estimation of CIs around
cost-effectiveness point estimates. Ninety-ﬁve percent conﬁdence
bounds around cost-effectiveness or CU can be calculated by
estimating the upper and lower 95% CIs around NMB and
solving for l where NMB = 0.
Health States
The model began with all patients disease-free after the comple-
tion of primary treatment (surgery, chemotherapy, and radio-
therapy, if applicable). Patients in the sequential adjuvant
trastuzumab arm received up to 12months of treatment as per the
HERA protocol, while the control arm received no further treat-
ment. In each monthly cycle, patients were at risk of transitioning
to LCR, well after LCR, DCR, and death (see Fig. 1). Patients in
LCRwere able to transition to well after LCR state; patients in the
DCR state remained in that state until death. Patients developing
a LCR were assumed to be at risk of a concurrent diagnosis of
DCR and at increased risk of a subsequent local or DCR (see
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Figure 1 Model schematic.
*Patients can receive only up to 1 year of trastuzumab therapy while in the Disease-Free, No Cardiotoxicity health state.
Table 1 Model assumptions
1. The event rates reported by the HERA trial are generalizable to our
hypothetical cohort.
2. Adjuvant hormonal therapy was not considered in the model.
3. There were no cancer recurrences beyond year 20 of the model.
4. The median age of the cohort at entry into the model was 49 years.
[16]
5. Cost parameters were based on a log-normal distribution with a
standard deviation of 0.25.
6. Patients could only develop cardiotoxicity while on active adjuvant
trastuzumab therapy.
7. Patients developing cardiotoxicity while receiving adjuvant trastuzumab
were excluded from further therapy.
8. Adjuvant trastuzumab patients experiencing cardiotoxicity within the
ﬁrst 3 months lost the beneﬁt of therapy and reverted to the baseline
risk of recurrence. Patients experiencing cardiotoxicity beyond the ﬁrst
3 months maintained the beneﬁt of therapy.
9. Symptomatic congestive heart failure (grade 3/4) was used as a proxy
measure for clinically signiﬁcant cardiotoxicity.
10. Median duration of cardiotoxicity was 49 months. [20]
11. Recurrent loco-regional disease and new contralateral breast cancers
were combined as local recurrences (LCR).
12. Patients with LCR were treated for 4 months then entered well, treated
state.
13. Twenty percent of patients with a LCR have a concurrent diagnosis of
DCR in ﬁrst month of LCR (“Concurrent DCR|LCR” in Table 2).These
patients immediately transition to the DCR health state.
14. The risk of a subsequent local or distant recurrence is doubled after an
initial LCR. (“RR[CR|LCR]” in Table 2)
15. Patients in the adjuvant trastuzumab arm experiencing a DCR less than
12 months from the end of therapy were not eligible for palliative
trastuzumab.
16. Eighty percent of eligible patients with DCR received palliative
trastuzumab (“Palliative Trastuzumab Eligible” in Table 2).
17. Patients could suffer two LCR.Any subsequent recurrences were distant.
18. Patients with DCR had a median survival of 21 months. [4,42]
19. Median survival of patients with DCR receiving palliative trastuzumab
was extended by 4 months. [4]
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Table 1). All patients were subject to age-speciﬁc background
mortality rates derived from Statistics Canada life tables [19].
As patients receiving adjuvant trastuzumab were considered
to be at increased risk of cardiotoxicity while they were receiving
trastuzumab, the disease-free, LCR, well after LCR, and DCR
health states were stratiﬁed by experience with or without car-
diotoxicity. In the model, trastuzumab patients developing symp-
tomatic cardiotoxicity were excluded from further treatment.
Patients in either arm experiencing cardiotoxicity could transi-
tion to the cardiotoxicity-free strata in subsequent months, based
on proportions reported by the National Surgical Adjuvant
Breast and Bowel Project (NSABP) B-31 trial in the absence of
equivalent published data from the HERA trial [20].
Outcomes were measured in terms of QALYs to simulta-
neously incorporate both increased survival and improved
quality-of-life. Utilities were assumed to be multiplicative, with
relative weights applied to a baseline utility of disease-free after
chemotherapy [21]. Baseline and relative quality weights were
derived from the literature [22–24].
Event Rates and Relative Beneﬁt
As the model used a time-dependent state-transition approach,
relative beneﬁt was based on the 3-year relative risk (RR) of
disease-free survival (i.e., cancer recurrence or death with or
without recurrence) derived from the updated HERA trial of
adjuvant trastuzumab after primary treatment for HER2/neu-
positive breast cancer, rather than the instantaneous hazard ratio
(HR) reported by Smith et al. [16].
For comparability with other published evaluations of adju-
vant trastuzumab, the primary analysis was based on a 5-year
duration of carryover beneﬁt. Nevertheless, because the updated
HERA results suggest that the statistically signiﬁcant duration of
beneﬁt may be less than 5 years, we conducted a secondary
analysis using a 3-year duration of beneﬁt. Beyond the relevant
duration of beneﬁt, the RR of a disease-free survival event with
adjuvant trastuzumab compared to the observation arm was set
to 1.0.
The baseline risk of cancer recurrence was derived from mul-
tiple sources. The baseline risk over the ﬁrst 3 years and the ratio
of local or regional recurrence to DCR was derived from the
HERA trial [16]. The medium-term (years 4–10) baseline risk
was derived from the HER2/neu-positive subgroup of the anthra-
cycline arm of the NSABP B-15 trial [25]. Average patient
follow-up in the NSABP B-15 trial was 12.4 years, and the 2-year
disease-free survival results approximated the HERA study
(74.3% vs. 77.4% in HERA). For years 11 to 20, the ratio of
annual recurrence between years 5 and 10 and years 10 and 15
from the Early Breast Cancer Trialists Collaborative Group
review of randomized trials [26] was applied to the recurrence
rates from years 5 to 10 of the NSABP B-15 trial [25]. It was
assumed that there were no further recurrences after 20 years.
The baseline rate and the RR of cardiac toxicity with adju-
vant trastuzumab were derived from the incidence of symptom-
atic congestive heart failure or cardiac death from the HERA trial
[16]. Because there were no cardiac deaths in the trastuzumab
arm of the trial, the model assumed no additional mortality as a
result of cardiotoxicity.
Costs
The analysis took a direct payer perspective, considering direct
costs to the health-care system and the patient. The costs of
incorporating trastuzumab in the adjuvant setting, including
HER2/neu screening, acquisition costs, drug administration, sup-
portive medications, and patient management were taken from
earlier cost studies conducted by members of the study team
[27,28]. The costs of palliative trastuzumab were based on a
local study of trastuzumab utilization in the palliative setting
[29]. In this study, patients received a median of 10 cycles over
7.2 months for an average cost of $28,495. Because local utili-
zation may not reﬂect wider practice patterns, the cost impact of
longer or shorter palliative trastuzumab therapy was tested in a
one-way sensitivity analysis. Management costs for local and
distant cancer recurrences were derived from a study based on
the Population Health Model developed by Statistics Canada
[30]. The costs of managing cardiotoxicity were taken from a
Canadian cost-effectiveness study [31].
Because none of the cost studies reported the variance of their
mean cost estimates, the probabilistic modeling assumed a log
normal distribution with a standard deviation of 0.25 for all cost
parameters. All costs were adjusted to 2007 Canadian dollars
(CDN$1.00 = US$0.94 [32]) based on the Statistics Canada con-
sumer price index, health and personal care component [33].
Sensitivity Analysis and Validation
Multivariate sensitivity analysis was conducted using probabilis-
tic modeling to generate 95% CIs around point estimates and a
cost-effectiveness acceptability curve that illustrates the probabil-
ity of trastuzumab being cost-effective over a range of possible
willingness-to-pay thresholds. Probabilistic modeling assigns
each input parameter a probability distribution and uses Monte
Carlo simulation to repeatedly sample values from that distribu-
tion [34]. Input parameters and their distribution, mean and
standard deviation are shown in Table 2. The modeling was
conducted using @Risk (Palisade Software, Newﬁeld, NY) with
10,000 iterations.
One-way sensitivity analysis was conducted to test the sensi-
tivity of results to the discounting of costs and beneﬁts, and to the
cost of palliative trastuzumab after DCR. Threshold analysis was
also conducted to identify the threhold values of key parameters
necessary to meet a $50,000 and a $100,000 per QALY gained
cost-effectiveness threshold, holding all other parameters con-
stant. Finally, because the model is a synthesis of a number of
data sources, the short-term disease-free survival estimates were
compared with disease-free survival results reported by the
HERA trial to assess the internal validity of the model.
Results
In the primary analysis, based on a 5-year duration of beneﬁt and
a 25-year analysis horizon, the cost-utility of sequential adjuvant
trastuzumab was $70,292 per QALY gained, shown in Figure 2a
by the point at which the expected NMB line crosses the hori-
zontal axis (i.e., NMB = 0). The upper and lower 95% conﬁ-
dence bounds of the CU estimate are shown by the points where
the dashed lines representing the upper and lower 95% conﬁ-
dence bounds for the NMB statistic cross the horizontal axis
(95% CI: $28,602–139,657 per QALY gained). Undiscounted
life expectancy was 18.9 years (95% CI: 15.7–22.9) in the adju-
vant trastuzumab arm and 17.2 years (95% CI: 14.5–20.6) in the
chemotherapy-only arm. In the secondary analysis (Fig. 2b),
based on a 3-year duration of beneﬁt, the CU results were con-
siderably less favorable, with an incremental cost-utility of
$127,862 (95% CI: $56,912–247,926). Complete incremental
results for both scenarios are presented in Table 3.
Cost-effectiveness acceptability curves for both scenarios,
shown in Figure 3, present the likelihood of sequential adjuvant
trastuzumab being cost-effective (i.e., NMB  0) over a range of
willingness-to-pay thresholds. For the primary analysis with a
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5-year carryover beneﬁt, there was a 25% likelihood of being
cost-effective at a $50,000 per QALY gained threshold and a
76% likelihood at a $100,000 per QALY gained threshold. For
the more conservative 3-year beneﬁt scenario, the likelihood of
being cost-effective was 3% and 34%, given thresholds of
$50,000 and $100,000 per QALY gained, respectively.
Sensitivity Analysis
The key drivers of net monetary beneﬁt in the reference scenario
were, unsurprisingly, the cost and relative beneﬁt of adjuvant
trastuzumab. Results of the threshold analysis for the primary
and secondary analyses are presented in Table 4, and show the
critical value along with the expected value and 95% CI of key
parameters in the model. The plausibility of a particular param-
eter meeting the critical value for a given threshold was judged
against the 95% CI. For the primary analysis with a 5-year
beneﬁt scenario, threshold values were more achievable at the
$100,000 than the $50,000 per QALY gained threshold. For the
3-year beneﬁt scenario, meeting a $50,000 per QALY gained
threshold was judged implausible as critical values were outside
the CI for all key parameters. Meeting a $100,000 threshold was
more plausible, because the critical values for adjuvant trastu-
zumab cost and relative beneﬁt fell within the CIs.
One-way sensitivity analyses of structural parameters in the
model showed that CU results were quite sensitive to discounting
(Table 5). CU was less favorable the higher the discount rate, but
the results were particularly sensitive to discounting outcomes.
The impact of palliative trastuzumab treatment after DCR was
also tested in a one-way sensitivity analysis because, in general,
the more expensive the consequences of recurrence, the more
cost-effective it is to prevent that recurrence. Increasing the
cumulative cost of palliative trastuzumab by 100% in the 5-year
scenario improved CU by 14% ($60,561/QALY gained),
although reducing the total cost by 50% worsened CU by 8%
($75,600/QALY gained). In the 3-year scenario, a 100% percent
increase in the cumulative cost of palliative trastuzumab
improved CU by 12% ($112,707/QALY gained), although
reducing the total cost by 50% worsened CU by 7% ($136,367/
QALY gained).
Model Validity
To test external validity, the model was compared with disease-
free survival end points at 3 years, as reported by the HERA trial
[16]. HERA reported an absolute disease-free survival difference
of 6.3%, although the model predicted a disease-free survival
differential of 6.1% (95% CI: 3.0–8.9%). Much of this differ-
ence may be attributed to the use of Canadian life tables to
estimate background mortality.
Discussion
The long-term CU of sequential adjuvant trastuzumab after che-
motherapy is primarily dependent on the magnitude and dura-
tion of clinical beneﬁt. In our analyses, CU was particularly
sensitive to the duration of carryover beneﬁt for trastuzumab
beyond the 3-year efﬁcacy results reported by the updated HERA
trial. The CU for sequential adjuvant trastuzumab, based on the
updated HERA results, was $72,292 and $127,862 per QALY
gained for the 5- and 3-year beneﬁt scenarios, respectively. More-
over, sequential adjuvant trastuzumab had a 76%—compared to
34%—likelihood of meeting a $100,000 per QALY threshold for
the 5- and 3-year scenarios, respectively. Under a more stringent
$50,000 threshold, the likelihood fell to 25% and 3%, respec-
tively.
It is important to note our estimates of long-term CU are
based on the recent update to the HERA trial [16] that reported
Table 2 Input parameters
Input parameter Distribution Mean SD Source
Age at entry Triangle 49 4.1 [16]
Average annual mortality rate Beta 0.009 0.004 [19]
RR, trastuzumab Beta/beta 0.754 0.059 [16]
Cancer recurrence
Baseline annual rate, years 1–5 Beta 0.094 0.005 [16]
Baseline annual rate, years 6–10 Beta 0.067 0.015 [25]
Baseline annual rate, years 11–20 Beta 0.046 0.010 [25,26]
Proportion local recurrence Beta 0.251 0.019 [16]
Concurrent DCR|LCR Beta 0.200 0.018 Ass’m (see Table 1)
RR (CR|LCR) Normal 2.001 0.249 Ass’m (see Table 1)
Palliative trastuzumab eligible Beta 0.800 0.040 Ass’m (see Table 1)
Median DCR survival (months) Poisson 20.895 4.576 [4–7]
Additional survival | herceptin Poisson 4.018 2.006 [4–7]
Total treatment cost
Adjuvant trastuzumab Log normal 51,693 13,284 [15,28,29]
Palliative trastuzumab Log normal 28,495 7,243 [28]
Symptomatic CHF Log normal 18,445 4,761 [31]
Local cancer recurrence Log normal 11,169 1,940 [30]
Distant cancer recurrence Log normal 33,872 8,329 [30]
Utility weights
Well, off treatment Beta 0.900 0.009 [24]
Well, on adjuvant trastuzumab Beta 0.922 0.008 [42]
Cardiotoxicity Beta 0.835 0.012 [22]
1st local cancer recurrence Beta 0.700 0.015 [24]
2nd local cancer recurrence Beta 0.500 0.016 [24]
Well after LCR Beta 0.900 0.009 [24]
DCR Beta 0.600 0.015 [24]
Cardiotoxicity
1-year baseline, symptomatic CHF Beta 0.002 0.001 [16]
RR, symptomatic CHF | aTZ Log normal 14.149 9.895 [16]
Median time with CHF (months) Derived from beta 49.57 4.99 [20]
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a less favorable relative disease-free survival advantage than
originally reported in the interim HERA analysis [8]. The HERA
update suggested that the hazard rates in the treatment and
control arms were converging at less than 5 years, but the true
duration of beneﬁt remained uncertain. The difference in CU
results between the 5- and 3-year beneﬁt scenarios in our analysis
highlights the need for longer follow-up in clinical trials to deﬁne
the true duration of adjuvant trastuzumab beneﬁt. Our measure
of relative beneﬁt was also based on the RR rather than the HR
of a disease-free survival event and was based on reported
disease-free survival end points at 3 years. Although the RR was
considerably less favorable than the reported HR (RR 0.75 vs.
HR 0.64), the instantaneous HR, derived from a Cox propor-
tional hazard survival model, does not specify how the risk of an
event changes over time, and consequently, “. . . its use to inform
time-dependency in Markov models is limited” [34]. Because our
model speciﬁcally incorporated time-dependent rates of recur-
rence and mortality, RR was felt to be the more appropriate
measure of relative clinical beneﬁt.
Previous CU estimates for sequential adjuvant trastuzumab
have been more favorable than our results, based on the 2-year
updated results. Nevertheless, these analyses were based on the
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Figure 2 (a) Net monetary beneﬁt adjuvant trastuzumab vs. primary treatment alone: 12-m treatment, 5-year beneﬁt, 25-year Horizon. (b) Net monetary beneﬁt
adjuvant trastuzumab vs. primary treatment alone: 12-m treatment, 3-year beneﬁt, 25-year horizon.
Cost-Utility of Sequential Adjuvant Trastuzumab 645
more the favorable interim results [8], used more favorable HRs
as the measure of relative beneﬁt, and assumed a longer duration
of beneﬁt. Many also consider the results over a longer analysis
horizon than used in our evaluation. A National Institute for
Clinical Excellence (NICE) guidance [35] reported a CU estimate
of £18,000 per QALY gained, based on a disease-free survival
HR of 0.54 and an assumption of a 5-year duration of beneﬁt.
The authors of the NICE report recently commented that the
updated HERA results is expected to increase (i.e., worsen) the
cost-effectiveness ratio associated with sequential trastuzumab
[36]. Millar and Millward also incorporated HRs from the
interim HERA analysis in a cost-effectiveness evaluation of
sequential adjuvant trastuzumab [37]. Assuming an 8-year
beneﬁt, they reported a CU of $22,793 per QALY gained (2005
Australian dollars) over a 51-year horizon. Finally, a Swiss study,
based on the interim HERA analysis and assuming a carryover
beneﬁt of 5-years, reported a cost-effectiveness of €19,673 per
quality-unadjusted life-year gained at 15 years, although a sen-
sitivity analysis reducing the carryover beneﬁt from 5 to 3 years
nearly doubled the cost-effectiveness estimate to €37,630 per
life-year gained [38].
Table 3 CU results
Scenario 1 Scenario 2
Analysis horizon 25 years 25 years
Treatment beneﬁt 5 years 3 years
Incremental cost $41,533 $43,094
95% CI $20,838–$71,410 $22,656–$72,906
Unadjusted life-years gained 0.77 0.51
95% CI 0.37–1.19 0.25–0.78
QALYs gained per patient 0.59 0.34
95% CI 0.51–0.76 0.29–0.40
CU at 25 years $70,292 $127,862
95% CI $28,602–$139,657 $56,912–$247,926
Net monetary beneﬁt -$11,990 -$26,242
@ $50,000 per QALY
95% CI -$50,134 to $19,872 -$61,006 to -$190
Net monetary beneﬁt $17,553 -$9,390
@ $100,000 per QALY
95% CI -$37,893 to $67,652 -$54,694 to $27,787
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Figure 3 Cost-effectiveness acceptability curve adjuvant trastuzumab vs. primary treatment alone scenario 1 and scenario 2.
Table 4 Threshold analysis
Parameter
Threshold value
$50,000/QALY
Threshold value
$100,000/QALY
Baseline value
in model (95% CI)
Scenario 1 (5-year beneﬁt)
Analysis horizon >60 years 14.7 years 25 years
Adjuvant trastuzumab treatment cost $40,369 $72,634 $51,693 ($31,014–83,421)
RR DFS event | adjuvant trastuzumab 0.698 0.822 0.754 (0.645–0.878)
Absolute rate of cardiotoxicity | adjuvant trastuzumab Not found 7.1% 2.5% (0.3–8.8%)
Scenario 2 (3-year beneﬁt)
Analysis horizon >60 years 33.8 years 25 years
Adjuvant trastuzumab treatment cost $25,676 $44,713 $51,693 ($31,014–83,421)
RR DFS event | adjuvant trastuzumab 0.526 0.729 0.754 (0.645–0.878)
Absolute rate of cardiotoxicity | adjuvant trastuzumab Not found 1.0% 2.5% (0.3–8.8%)
Cells in bold indicate threshold values falling within 95% CI of model parameter.
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CU estimates for sequential adjuvant trastuzumab based on
the updated HERA results with a median 2-year follow-up,
including our study, have been less favorable. A recent evaluation
by Lidgren et al. applied efﬁcacy estimates from the updated
HERA study to a baseline breast recurrence risk derived from a
Swedish cohort [39]. Assuming a lifetime duration of beneﬁt,
they reported a CU of €36,000 per QALY gained with sequential
adjuvant trastuzumab after HER2/neu testing compared to con-
ventional treatment. Nevertheless, in a sensitivity analysis, apply-
ing a more conventional assumption of a 5-year duration of
beneﬁt, they found the CU to be in the range of €66,800 per
QALY gained. A Japanese study estimated the cost per quality-
unadjusted life-year gained over a 50-year horizon to be €40,000
and €17,000 for 2- and 5-year carryover beneﬁt scenarios,
respectively [40]. This analysis was based on net treatment costs
of approximately €24,000 to €22,000, reﬂecting lower average
body weight (50–60 kg) and lower drug acquisition costs of
trastuzumab in Japan. A sensitivity analysis adjusting for weight
(60–75 kg) increased cost-effectiveness to €49,000 and €22,000
per life-year gained for the 2- and 5-year carryover scenarios.
Adjusting for international differences in acquisition costs would
further inﬂate these estimates of cost-effectiveness. Finally, costs
per unadjusted life-year gained reported in the Swiss and Japa-
nese studies are expected to be more favorable than the costs per
QALY gained reported in our evaluation. Overall, CU estimates
based on the updated HERA results suggests that the true cost-
effectiveness of sequential adjuvant trastuzumab may be less
favorable than earlier estimates.
CU analyses of concurrent adjuvant trastuzumab, based on
the joint analysis of the NSABP-B31 and NTCTG-N9831
studies [9], appear more favorable. Liberato et al. reported CU
estimates of €14,861 per QALY gained from the perspective of
the Italian health-care system and US$18,970 per QALY gained
from a US health-care perspective, both over a 15-year analysis
horizon [41]. Kurian et al. reported a CU estimate of US$39,982
per QALY gained over a lifetime horizon [42]. Finally, Garrison
et al. reported a CU of US$26,417 over a lifetime horizon and
US$34,201 over a 20-year horizon [43]. Because the costs,
health states, and assumptions included in our model were spe-
ciﬁc to the sequential approach studied in the HERA trial, these
results cannot be generalized to the concurrent strategy. Direct
clinical and economic comparisons between the sequential and
concurrent approaches, however, should only be conducted
after the mature results of the NCCTG-N9831 study become
available.
There remains considerable uncertainty around the optimal
schedule and duration of adjuvant trastuzumab treatment.
Reﬂecting trial protocols and current international practice, our
analysis and all those mentioned previously modeled 1 year of
adjuvant trastuzumab therapy, either sequential or concurrent to
adjuvant chemotherapy. The FinHer study, however, suggests
that a similar relative beneﬁt may be possible with just 9 weeks
of adjuvant trastuzumab therapy [11]. If conﬁrmed by a larger
trial, the CU of adjuvant trastuzumab would be considerably
more favorable than current estimates.
There were several limitations to our analysis. First, our
analysis was based on estimates of efﬁcacy under controlled
conditions rather than effectiveness in actual clinical practice. It
is likely that the observed clinical beneﬁt of adjuvant trastu-
zumab in routine clinical practice—and hence the CU—will be
less favorable than that observed in strictly monitored clinical
trials. Second, the HERA trial allowed patients in the control
arm to switch to the trastuzumab arm after the ﬁrst interim
report suggested the clinical beneﬁt of aTZ. Although this
unplanned crossover reﬂects ethical research practice, it could
potentially bias the updated HERA results. Nevertheless, it is
impossible to predict the net effect of the crossover, and the
authors report that the intent-to-treat and censored HRs in the
updated HERA analysis were essentially the same (0.64 vs.
0.63, respectively) [16]. Third, the model relied on symptomatic
congestive heart failure as a proxy measure of clinically signiﬁ-
cant cardiotoxicity, and adapted long-term recovery data from
the NSABP B-31 trial of concurrent adjuvant trastuzumab [20].
Future research should aim to clarify the incidence and conse-
quences of cardiotoxicity associated with trastuzumab therapy
in routine practice. Fourth, the probabilistic analysis was forced
to rely on assumptions regarding the variance of the cost
parameters. Although this weakens the empirical basis of the
input distributions, we feel that it represents an improvement
over a strictly deterministic approach. Fifth, we took a direct
payer rather than a societal cost perspective that would include
costs such as lost productivity and caregiver time. A direct payer
perspective was felt to be most relevant to health-care payers,
considering coverage decisions around breast cancer treatments,
and to be most comparable with previous economic evaluations
of adjuvant trastuzumab. Including indirect costs would likely
improve the relative cost-effectiveness of adjuvant trastuzumab.
Finally, in the absence of an accepted cost-effectiveness thresh-
old, we judged the favorability of our CU estimates relative to
the common yet ultimately arbitrary thresholds of $50,000 and
$100,000 per QALY gained. Further research is required to
identify an appropriate and meaningful cost-effectiveness
threshold [44].
In summary, the CU of sequential adjuvant trastuzumab after
chemotherapy relative to chemotherapy alone is dependent on
the cost of trastuzumab therapy and the magnitude and duration
of beneﬁt achieved. Based on the updated HERA results, we
estimated the CU of adjuvant sequential trastuzumab to be
$72,292 per QALY gained based on a 5-year duration of beneﬁt,
and $127,862 per QALY with a 3-year duration of beneﬁt over
a 25-year analysis horizon. The sensitivity of these results to the
relative beneﬁt observed in the updated 3-year results versus the
interim 2-year results and to assumptions around the duration of
carryover beneﬁt highlights the need for further clinical research
to determine the true magnitude and duration of clinical beneﬁt
and the associated CU of sequential adjuvant trastuzumab in
HER2/neu-positive breast cancer.
Source of ﬁnancial support: Department ofMedicine, Dalhousie University.
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